Table 1 Characteristics of women included in the study cohort, by post-diagnosis statin exposure, with statin initiation rate

From: De novo post-diagnosis statin use, breast cancer-specific and overall mortality in women with stage I–III breast cancer

 

De novo statin use post breast cancer diagnosis a , b

Characteristic

Non-user ( N =2759)

User ( N =837)

Initiation rate (per 1000 person years), associated P -value

Age in years

Median (IQR)

66 (58, 73)

65 (58, 72)

 

—

Comorbidity score c

Median (IQR)

6 (3, 11)

7 (3, 11)

 

—

Smoking (%)

Current

583 (21.1)

171 (20.4)

41.3

0.53

Past

306 (11.1)

106 (12.7)

47.5

 

Never

1324 (48.0)

422 (50.4)

43.8

 

Unspecified

546 (19.8)

138 (16.5)

38.8

 

Aspirin (%) c

Yes

432 (15.7)

153 (18.3)

49.2

0.06

No

2327 (84.3)

684 (81.7)

41.6

 

NSAID (%) c

Yes

1178 (42.7)

384 (45.9)

44.8

0.22

No

1581 (57.3)

453 (54.1)

41.2

 

Anti-diabetic (%) c , d

Yes

60 (2.2)

38 (4.5)

74.7

0.001

No

2699 (97.8)

799 (95.5)

41.9

 

Bisphosphonate (%) c

Yes

198 (7.2)

46 (5.5)

39.4

0.40

No

2561 (92.8)

791 (94.5)

43.0

 

Tumour stage (%) d , e

I

917 (33.2)

297 (35.5)

44.1

0.02

IIa

843 (30.6)

297 (35.5)

47.5

 

IIb

610 (22.1)

162 (19.4)

38.0

 

IIIa

166 (6.0)

40 (4.8)

39.6

 

IIIb–c

223 (8.1)

41 (4.9)

31.7

 

Tumour grade (%)

Low

301 (10.9)

101 (12.1)

44.8

0.18

Intermediate

1357 (49.2)

416 (49.7)

43.9

 

High

866 (31.4)

254 (30.4)

42.4

 

Unspecified

235 (8.5)

66 (7.9)

35.8

 

ER (%) d

Negative

471 (17.1)

110 (13.1)

35.3

0.01

Positive

2028 (73.5)

610 (72.9)

43.7

 

Unspecified

260 (9.4)

117 (14.0)

47.5

 

PR (%)

Negative

717 (26.0)

179 (21.4)

39.2

0.22

Positive

1393 (50.5)

415 (49.6)

44.7

 

Unspecified

649 (23.5)

243 (29.0)

42.7

 

HER2 (%)

Negative

1679 (60.9)

419 (50.1)

40.8

0.06

Positive

339 (12.3)

99 (11.8)

44.7

 

Unspecified

741 (26.9)

319 (38.1)

45.1

 

Chemotherapy (%) f

Yes

1123 (40.7)

344 (41.1)

43.2

0.78

No

1636 (59.3)

493 (58.9)

42.5

 

Anti-oestrogen (%) f

Yes

2065 (74.9)

642 (76.7)

43.8

0.25

No

694 (25.1)

195 (23.3)

39.9

 
  1. Abbreviations: ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; IQR=interquartile range; NSAID=non-steroidal anti-inflammatory drug; PR=progesterone receptor.
  2. aNo statin use in the year prior to diagnosis and at least one statin prescription received between diagnosis and the end of follow-up, 31 December 2011.
  3. bPatients identified as statin users/non-users after lagging exposure by 2 years.
  4. cIn the year prior to breast cancer diagnosis.
  5. dDifference in statin initiation rate P<0.05 (Poisson regression).
  6. eAJCC Cancer Staging Manual 6th Edition. Springer, 2002.
  7. fIn the year post breast cancer diagnosis.
Back to article page